rare connect
National Comprehensive Cancer Network (NCCN) Guidelines for Histiocytosis
Published March 2021
The ECDGA is pleased to announce that the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—has published a new NCCN Guidelines® for Histiocytosis. These clinical practice guidelines provide the latest evidence and expert-consensus for diagnosing and treating the three most common forms of histiocytosis in adults: Langerhans cell histiocytosis (LCH), Erdheim-Chester Disease (ECD,) and Rosai Dorfman Disease (RDD).
The NCCN Guidelines can help patients, families, and physicians access the latest information about symptoms, diagnosis, treatment, and more. The guidelines can also serve as a useful tool when seeking approvals for coverage of drugs and therapies. Access your copy with a free NCCN account, which many physicians actively use in their practices. The guidelines are updated at least once a year and can be accessed at any time. You can view the published guidelines on NCCN’s website within the following link, (listed as “histiocytic neoplasms”).
We encourage you to share this information with your healthcare team.
